ThursdayJan 20, 2022 1:20 pm

Nemaura Medical Inc. (NASDAQ: NMRD) Firmly Positioned in Growing Diabetes Tech Market With Recent CGM Shipment to UK Licensee

Diabetes tech market expanded in 2021 due to new users, growing demand for CGM devices, coverage of CGM devices by CMS  Diabetes is a growing problem in the US. According to CDC, roughly 1 in 10 Americans have diabetes, and 1 in 3 have pre-diabetes NMRD currently commercializing the sugarBEAT(R) non-invasive and flexible continuous glucose monitor Company recently completed initial shipment to UK licensee While most medical technology businesses faced COVID-19-related restrictions (https://ibn.fm/NJbOa), Nemaura Medical (NASDAQ: NMRD), a medical technology company that develops affordable diagnostic and digital tools for diabetes management, is favorably positioned in the rapidly growing diabetes tech…

Continue Reading

ThursdayJan 20, 2022 9:30 am

Study Finds That New Lung Cancer Screening Guidelines Increase Eligibility for Black Women

A new study conducted by researchers from the University of California-Berkeley, the Northeastern University and Boston University has found that the new screening guidelines for lung cancer have significantly grown the eligibility of Black women. The U.S. Preventative Services Taskforce, which is made up of experts in evidence-based and preventative medicine, changed the lung cancer screening guidelines in April 2021 by reducing the required smoking “pack-years” to 20 from 30 and lowering the screening age of eligibility to 50, from 55. According to a research letter recently published in “JAMA Oncology,” these changes were made in order to increase the…

Continue Reading

WednesdayJan 19, 2022 9:30 am

Study Suggests HIV Drugs Could Have Place in Brain Cancer Treatment

A new study conducted by researchers at the Brain Tumor Research Center at the University of Plymouth has found that the drugs used to treat HIV and AIDS may be effective in the treatment of low-grade brain tumors. The study’s researchers believe that ARVs could be prescribed for patients who have been diagnosed with acoustic neuroma and meningioma brain tumors, which often grow back after radiotherapy and surgery. Meningioma is a common primary tumor that may become cancerous as time goes by. This tumor develops from cells found in the meninges, which protect the spinal cord and the brain. On…

Continue Reading

WednesdayJan 19, 2022 9:00 am

Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) CEO Shares Company Success Insights on Bell2Bell Podcast

Mr. Josh Bartch, the CEO, Chairman, and Co-Founder of Mydecine, attributed the company’s success to its phased approach to product research and development He noted significant strides in smoking cessation and PTSD research over the 2021 calendar year, which will be integral to operations in the new year Mr. Bartch was also proud of the current efficacy data around psilocybin to treat nicotine dependance which is significantly better than what is available in the market Going into 2022, Mydecine will embark on more clinical studies on smoking cessation and PTSD, focus more on novel compound production and growing its Mindleap…

Continue Reading

WednesdayJan 19, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Emerging as Psychedelics Leader, Looking Forward to ‘Transformative’ Year

Company marked host of major milestones and accomplishments in 2021 Approvals, licenses, expansions and growth all essential pieces of Cybin success CYBN’s innovative operational and R&D pipeline platforms expected to support four first-in-human clinical studies in 2022 As the new year begins, Cybin (NEO: CYBN) (NYSE American: CYBN) couldn’t be in a better position. The biopharmaceutical company’s commitment to establishing a stronghold in the psychedelics space paid off big last year, with the company marking a host of major milestones and accomplishments and looking toward more of the same for 2022.  "2021 was an exciting year for Cybin,” said Cybin CEO…

Continue Reading

TuesdayJan 18, 2022 9:30 am

AI Could Help Relieve Physician Stress

A report recently released by Medscape shows that more than 40% of physicians in the United States suffer from burnout. Burnout not only affects individuals emotionally but also impacts finances negatively, with data from the American Medical Association showing that burnout costs healthcare organizations $500,000 to $1 million per physician. The cost of burnout also includes indirect costs such as decreased patient satisfaction, lost patient care revenue, higher risk of malpractice suits, medical errors and damage to the reputation of the healthcare organization. The pandemic has only made things worse, with stress becoming a severe issue for doctors these last…

Continue Reading

FridayJan 14, 2022 9:30 am

Study Finds That PTSD Symptoms Change During Menstrual Cycle

A new study has found that over the course of the menstrual cycle, the symptoms of post-traumatic stress disorder may vary, with fewer symptoms presenting as a woman moves closer to ovulation and more symptoms presenting during the first few days of the cycle. The study was carried out by researchers from the Thomas Jefferson University, with its findings being published in the “Psychological Trauma: Theory, Research, Practice and Policy Journal.” The researchers found that estradiol, which is an estrogen hormone produced in the female body, was responsible for this change. This hormone regulates the reproductive cycle in women. The…

Continue Reading

ThursdayJan 13, 2022 9:30 am

Long-Term Opioid Users at Risk of Depression, Study Finds

A new study has found that near-daily or everyday use of prescription opioids is linked to a higher risk of new onset depression, in comparison with occasional use of the drugs. While the number of new opioid prescriptions in the United States has dropped since 2012, the average duration of prescriptions and the proportion of 30-day opioid prescriptions increased between 2006 and 2017. The study was conducted by researchers at St. Louis University School of Medicine, led by Jeffrey Scherrer, the institution’s senior director of the Advanced Health Data Institute. Scherrer stated that the risk for new depression episodes in…

Continue Reading

WednesdayJan 12, 2022 9:30 am

Researchers Explore How Pandemic Impacted Breast Cancer Screening in Low-Income Populations

After lung cancer, breast cancer is the deadliest type of cancer in the world, affecting women of all ages. Estimates show that about 13% of women develop the deadly cancer in their lifetime. In 2020, more than 2.2 million women were diagnosed with breast cancer, with some 680,000 succumbing to the ailment. These stats highlight the importance of early detection, which is mainly accomplished through breast cancer screening, in helping reduce mortality. Unfortunately, the onset of the coronavirus pandemic caused many postponements and cancellations in screenings not only for breast cancer but also other types of cancer. As a result,…

Continue Reading

WednesdayJan 12, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes ‘Milestone’ Step with USPTO Notice of Allowance CYB004

Cybin awarded notice for company’s innovative treatment of anxiety disorders Approval demonstrates company’s dedication to discovery and development of psychedelic-based compounds for addressing mental health Anxiety disorders rank among the most common mental illnesses in the country Cybin (NEO: CYBN) (NYSE American: CYBN) has taken another step forward in its strategic plan to strengthen its position as leading innovator in developing putative psychedelic compounds. The company has received a Notice of Allowance from the U.S. Patent and Trademark Office (“USPTO”) for its patent application for an innovative treatment of anxiety disorders (https://ibn.fm/8hMWh). Cybin announced that it has been awarded a USPTO…

Continue Reading

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050